Similarly, IDH1 and IDH2 gain-of-function mutations in leukemia lead to the accumulation of the competitive inhibitor of TET enzymes, 2-hydroxyglutarate (2-HG), with consequent DNA hypermethylation. This evidence concerns the gene IDH1 and leukemia.